Accentus Medical Advances Application of Agluna® for Cardiac Device Applications

19 May 2017

Accentus Medical, a leading developer of advanced surface modifications and coating technologies for implantable medical devices, is pleased to announce a funding award of £149,199 from Innovate UK, the UK’s innovation agency. The award is targeted towards a project focused on testing the safety and efficacy of Agluna® silver ion-based antimicrobial surface treatment applied to titanium casing of cardiac implantable electronic devices (CIEDs). A parallel work package within the project is targeting development and proof of concept testing of a biocompatible, anti-microbial surface on a novel cardiac device.

Implantation rates of CIEDs, including pacemakers, are rising with an expanding range of clinical indications, and as populations age. CIEDs lower the risk of arrhythmia deaths and improve quality of life, but device-related infection can be devastating for the patient and costly for healthcare providers. This is a multi-£billion global socioeconomic problem seeking technology solutions.

With a track record of successful clinical application in the orthopaedic limb salvage sector, Accentus Medical is now advancing application of its innovative, cost effective and clinically proven Agluna® surface technology to titanium CIED casings, to help mitigate the incidence and severity of CIED related infection.

This project follows a previous study successfully carried out by Accentus Medical, with grant funding support from Innovate UK’s Proof of Concept award scheme, which investigated the biocompatibility and pacing function of Agluna®-treated CIEDs. The outcomes of that study have recently been published in peer-reviewed BMJ Open Heart journal:

This current funding award has been received from Innovate UK’s Medical Technologies Launchpad Wales, and successful completion of the project will catalyse future development of Accentus Cardiac (Accentus Medical’s sister company) within the South Wales medtech cluster.

Dr Ameet Bakhai, Advisor on Cardiology to Accentus Medical, said: “Multiple studies have highlighted the rising cost of combined medical and surgical treatment of CIED related infections. With increasing global concerns about antibiotic resistance, there is a strong market driver for introducing a proven, cost effective silver ion based technology such as Agluna® to clinical adoption on CIEDs. This innovative technology has considerable potential to improve patient outcomes and reduce the economic burden of treating CIED infections. By treating the device surface as an integral part of the manufacturer’s standard manufacturing processes, Agluna® will reduce the time and procedural complexity of other clinical approaches, including the use of antibiotic-loaded pouches or the application of topical agents at the time of surgery.”
For further information, please contact:
Accentus Medical
T: +44 (0)1235 434320

Download PDF

Contact Us

T: +44 (0)1235 434 320
F: +44 (0)1235 434 329